This trial is for a new treatment of cancer in the salivary gland. It is testing a new drug, APG-115, with or without another drug, Carboplatin. Part 1 had 2 groups, but one group did not have the new drug APG-115 and was not doing well, so that group was stopped. Part 2 is just testing APG-115 by itself.
3 Primary · 5 Secondary · Reporting Duration: Until death or end of study; up to approximately 5 years
34 Total Participants · 2 Treatment Groups
Primary Treatment: APG-115 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: